北陆药业

300016 SZSE 证监会行业分类 C27医药制造业

Key Metrics

Market Cap

5.6B ($813.4M)

P/E Ratio

N/A

P/B Ratio

N/A

Revenue

984.0M

Net Income

267,700

Gross Margin

N/A

Op. Margin

-0.1%

Net Margin

0.0%

ROE

0.0%

ROA

0.0%

D/E

0.63

Dividend Yield

N/A

EPS

0.09

Current Ratio

2.57

Price History

Company Info

Industry	C27医药制造业
Market Segment	ChiNext
Currency	CNY
Fiscal Year	2024

Business Overview

Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride and repaglinide tablets and jiuwei zhenxin granules. It also offers gadolinium-based agents, including gadopentetate dimeglumine and gadobutrol, as well as iodine-based agents comprising iohexol, iover...

Full Financials Advanced Charts Filings

Peers

工商银行

601398

2.7T

P/E: 7.6

建设银行

601939

2.5T

P/E: 7.2

农业银行

601288

2.4T

P/E: 8.7

中国海油

600938

2.0T

P/E: 16.2

宁德时代

300750

1.9T

P/E: 25.6

贵州茅台

600519

1.8T

P/E: 20.1

中国银行

601988

1.8T

P/E: 7.3

中国人寿

601628

1.2T

P/E: 6.9

Financial Statements

Loading financials...

Open Advanced Charts

Full charting with technical indicators, candlestick, and more.

About 北陆药业

Ticker	300016
Exchange	SZSE
Sector	证监会行业分类
Industry	C27医药制造业